Humanigen Wilts after COVID-19 Antibody Fails NIH Trial

Lenzilumab missed its primary endpoint in the ACTIV-5/BET-B trial, conducted by the NIH’s National Institute of Allergy and Infectious Diseases. The study compared whether lenzilumab plus Gilead Sciences’ Veklury® (remdesivir) was more effective than placebo plus remdesivir in…

Source: www.genengnews.comRead more